Product Watermark Icon
VirD Icon

VirD™ Functional Membrane Protein Virion Display Microarray

Functional GPCRs Embedded in a Cell Membrane

Revolutionary viral-based expression technology for functional membrane protein analysis with unprecedented accuracy

REQUEST INFO

Advanced Viral Display Technology

G protein-coupled receptors (GPCRs) and membrane proteins are notoriously difficult to study due to their complex folding requirements and membrane dependencies. Traditional expression systems often fail to produce functional proteins.

VirD™ technology overcomes these limitations by utilizing a sophisticated viral-based expression system that maintains protein functionality while enabling high-throughput analysis on microarray platforms.

VirD Overview Figure

VirD Membrane Protein Array Validation and Production

VirD is a microarray that uses virions to display functional membrane proteins like GPCRs and is useful for drug development and functional assays.

VirD Membrane Protein Array Validation and Production Figure

VirD Applications

VirD membrane protein technology has a range of applications across various fields in life sciences and biotechnology. Here are some key applications:

Drug Discovery and Development

Identify and characterize potential drug targets, particularly membrane proteins like G protein-coupled receptors (GPCRs), ion channels, and transporters.

Biomarker Discovery

Discover and characterize membrane proteins that serve as biomarkers for diseases, i.e., cancer research and diagnostics, where specific membrane proteins may indicate disease presence or progression.

Protein Interaction Studies

Investigate protein-protein interactions involving membrane proteins – critical for understanding signaling pathways and cellular communications.

Therapeutics Production

Produce therapeutic proteins, including antibody fragments or fusion proteins that target membrane proteins, enhancing the potential for novel treatments.

Functional Characterization

Study the functional properties of membrane proteins in native-like environments; assess how these proteins interact with ligands, their conformational changes, and their role in cellular processes.

Why Choose VirD Technology?

Choosing VirD membrane protein technology offers several compelling advantages that make it an attractive option for researchers and companies involved in the study and application of membrane proteins. Here are some key reasons:

Proper Protein Folding

Our patented viral-based expression system ensures GPCRs and membrane proteins maintain their native conformation and functionality, embedded in authentic cell membranes.

Eliminates Interference

Unlike traditional cell-based systems, VirD microarrays eliminate endogenous receptor competition, providing cleaner, more interpretable experimental data.

High-throughput Analysis

Microarray format enables simultaneous analysis of multiple GPCRs and membrane proteins, accelerating drug discovery and functional studies.

Validated Drug Targets

Focus on clinically relevant GPCRs and membrane proteins that are critical for drug development and therapeutic intervention.

Drug Discovery

VirD plays a critical role in early-stage drug discovery, especially for therapeutics targeting membrane proteins which are important drug targets.

VirD Technology Overview

VirD, a viral-based expression technology, expresses individual GPCR proteins embedded in a cell membrane. Purified virions displaying correctly-folded GPCRs are printed onto glass to create VirD arrays. This method eliminates the problem of endogenous receptor competition when using traditional methods, and yields much cleaner data.

What Our Customers Are Saying

"With CDI Labs, identifying antibodies and their targets has never been so simple. Their passionate team, robust science and high-quality service unlock the discovery of new mechanisms, biomarkers and therapeutic targets."

Matthieu Roulleaux DugageGustave Roussy View poster, "Baseline serum level of IgG targeting annexin A2 is predictive of response to immunotherapy in patients with advanced NSCLC" presented at IMMUNOLOGY 2025

What Our Customers Are Saying

"We enjoyed working with CDI Labs. We used both VirScan and HuScan services from CDI Labs as part of our neurodegenerative disease research. The team at CDI Labs was very responsive and great to work with, and they went above and beyond to get us our results very quickly. They were particularly helpful in making contract arrangements and ensuring that everything was in place for a smooth collaboration. CDI Labs also provided a comprehensive statistical analysis, which will be invaluable as we build on our research. We’re still analyzing the data, but we’re confident that we’ll gain new insights into disease mechanisms that will advance our research."

Wouter Peelaerts, PhDProfessor, KU Leuven

What Our Customers Are Saying

"CDI Labs provide consistent service and consistently high-quality protein array products to our lab. Their sales and scientific team are courteous and timely in their responses to our queries.”

Dr. Andrew McKeonMayo Clinic College of Medicine & Science

Data and Technology Validated by Scientists

"We elected to use the HuProt Microarray because it is an extensive platform that contains over 21,000 unique, individually purified full-length human proteins and protein isoforms in duplicate, covering more than 81% of the proteome."

OncologistSchool of Medicine Research (as mentioned in "Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade" - AACR Clinical Caner Research - September 2022)

Data and Technology Validated by Scientists

"This (VirScan) assay, which uses phage display immunoprecipitation and sequencing, is a sensitive and focused high-comprehensive approach that enables thorough serological profiling of antiviral antibodies in humans and, consequently, the identification of viral exposure throughout the human virome."

Faculty of MedicineResearch Institution (as mentioned in "Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC" - Science Advances - November 2023)

Data and Technology Validated by Scientists

"By using (HuProt) protein arrays, we were able to evaluate a broader range of antigens compared to previous investigations."

Senior ScientistBiotech Research (poster presentation at the San Antonio Breast Cancer Symposium 2023)